Cerebellar Amyloid-β Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios?

SUV ratios (SUVRs) are used for relative quantification of 18F-florbetaben scans. The cerebellar cortex can be used as a reference region for quantification. However, cerebellar amyloid-β (Aβ) plaques may be present in Alzheimer disease (AD). The aim of this study was to assess the influence of Aβ pathology, including neuritic plaques, diffuse plaques, and vascular deposits, in 18F-florbetaben SUVR when cerebellum is used as the reference. Methods: Using immunohistochemistry to demonstrate Aβ plaques and vascular deposits, and using the Bielschowsky method to demonstrate neuritic plaques, we performed a neuropathologic assessment of the frontal, occipital, anterior cingulate, and posterior cingulate cerebral cortices and the cerebellar cortex of 87 end-of-life patients (64 with AD, 14 with other types of dementia, and 9 nondemented aged volunteers; mean age ± SD, 80.4 ± 10.2 y) who had undergone 18F-florbetaben PET before death. The lesions were rated as absent (none or sparse) or present (moderate or frequent). Mean cortical SUVRs were compared among cases with different cerebellar Aβ loads. Results: None of the 83 evaluable cerebellar samples showed frequent diffuse Aβ or neuritic plaques; 8 samples showed frequent vascular Aβ deposits. Diffuse Aβ plaques were rated as absent in 78 samples (94%) and present in 5 samples (6%). Vascular Aβ was rated as absent in 62 samples (74.7%) and present in 21 samples (25.3%). No significant differences in cerebellar SUVs were found among cases with different amounts or types of Aβ deposits in the cerebral cortex. Both diffuse and neuritic plaques were found in the cerebral cortex of 26–44 cases. No significant SUVR differences were found between these brains with different cerebellar Aβ loads. Conclusion: The effect of cerebellar plaques on cortical 18F-florbetaben SUVRs appears to be negligible even in advanced stages of AD with a higher cerebellar Aβ load.

[1]  A. Larner The cerebellum in Alzheimer's disease. , 1997, Dementia and geriatric cognitive disorders.

[2]  Nick C Fox,et al.  Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. , 2011, Brain : a journal of neurology.

[3]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[4]  L. Wolfson,et al.  Cardiovascular risk factors and small vessel disease of the brain: Blood pressure, white matter lesions, and functional decline in older persons , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  Kenneth S. Kosik,et al.  The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology , 1996, Nature Medicine.

[6]  John Seibyl,et al.  Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study , 2016, The Journal of Nuclear Medicine.

[7]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[8]  D. Selkoe,et al.  Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. , 1989, The American journal of pathology.

[9]  William D Rooney,et al.  Longitudinal relaxographic imaging of white matter hyperintensities in the elderly , 2014, Fluids and Barriers of the CNS.

[10]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  L. Dinkelborg,et al.  Piramal Imaging. , 2015, Neurodegenerative disease management.

[12]  Lennart Thurfjell,et al.  The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data , 2015, Alzheimer's & Dementia.

[13]  S. Hirai,et al.  Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated byβ protein immunostain , 2004, Acta Neuropathologica.

[14]  W. Markesbery,et al.  Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. , 1999, Alzheimer disease and associated disorders.

[15]  B. Jasani,et al.  The distribution of amyloid plaques in the cerebellum and brain stem in Down's syndrome and Alzheimer's disease: a light microscopical analysis , 2004, Acta Neuropathologica.

[16]  H. Braak,et al.  Alzheimer's disease: Mismatch between amyloid plaques and neuritic plaques , 1989, Neuroscience Letters.

[17]  B. Ghetti,et al.  Spectrum of amyloid β-protein immunoreactivity in hereditary Alzheimer disease with a guanine to thymine missence change at position 1924 of the APP gene , 1992, Brain Research.

[18]  C. Rowe,et al.  Amyloid imaging in therapeutic trials: The quest for the optimal reference region , 2015, Alzheimer's & Dementia.

[19]  Majaz Moonis,et al.  Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees , 2007, The Journal of Neuroscience.

[20]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[21]  Lutz Tellmann,et al.  Comparison of cerebral blood flow acquired by simultaneous [15O]water positron emission tomography and arterial spin labeling magnetic resonance imaging , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  John Seibyl,et al.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.

[23]  Cerebral amyloid angiopathy and intracerebral hemorrhage with special reference to the pons. , 1994, Clinical neuropathology.

[24]  P. Wood The Cerebellum in AD , 2003 .

[25]  C. Rowe,et al.  18F-Florbetaben (FBB) PET SUVR quantification: Which reference region? , 2015 .

[26]  John Seibyl,et al.  Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[27]  Lennart Thurfjell,et al.  Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads , 2014, The Journal of Nuclear Medicine.

[28]  R. Waggoner,et al.  FAMILIAL ORGANIC PSYCHOSIS (ALZHEIMER'S TYPE) , 1934 .

[29]  N. Foster,et al.  Preserved Pontine Glucose Metabolism in Alzheimer Disease: A Reference Region for Functional Brain Image (PET) Analysis , 1995, Journal of computer assisted tomography.

[30]  John Seibyl,et al.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.

[31]  Matthew L Senjem,et al.  Functional impact of white matter hyperintensities in cognitively normal elderly subjects. , 2010, Archives of neurology.